Solubilized Ibuprofen: Evaluation of Onset, Relief, and Safety of a Novel Formulation in the Treatment of Episodic Tension‐type Headache

Packman, Barry; Packman, Elias W.; Doyle, Geraldine; Cooper, Stephen A.; Ashraf, Elizabeth; Koronkiewicz, K; Jayawardena, Shyamalie

doi:10.1046/j.1526-4610.2000.00087.x

Cited by 75 publications

(55 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ibuprofen lysine 400 mg produces faster onset and higher peak analgesia than a conventional tablet of ibuprofen acid 400 mg in dental pain. 29 Solubilized liquigel ibuprofen 400 mg had more rapid onset than acetaminophen 1000 mg and had a longer duration of action than either acetaminophen 1000 mg or ketoprofen 25 mg. 30 These differences can be clinically important as the median time to clinically meaningful relief of pain was shorter after solubilized ibuprofen 400 mg than after acetaminophen 1000 mg. 31 The solubilized potassium liquigel formulation of ibuprofen is available over-the-counter worldwide. Diclofenac sodium softgel has also been shown to provide a very rapid onset of analgesic activity and prolonged analgesic duration compared with conventional diclofenac potassium.…”

Section: Effects Of Formulation On the Analgesic Activity Of Nsaidsmentioning

confidence: 99%

An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs

Ong¹,

Lirk²,

Tan³

et al. 2007

Clinical Medicine & Research

482

286

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs (NSAIDs), including both traditional nonselective NSAIDs and the selective cyclooxygenase (COX)-2 inhibitors, are widely used for their anti-inflammatory and analgesic effects. NSAIDs are a necessary choice in pain management because of the integrated role of the COX pathway in the generation of inflammation and in the biochemical recognition of pain. This group of drugs has recently come under scrutiny because of recent focus in the literature on the various adverse effects that can occur when applying NSAIDs.This review will provide an educational update on the current evidence of the efficacy and adverse effects of NSAIDs. It aims to answer the following questions: (1) are there clinically important differences in the efficacy and safety between the different NSAIDs, (2) if there are differences, which are the ones that are more effective and associated with fewer adverse effects, and (3) which are the effective therapeutic approaches that could reduce the adverse effects of NSAIDs. Finally, an algorithm is proposed which delineates a general decision-making tree to select the most appropriate analgesic for an individual patient based on the evidence reviewed. Keywords: Analgesics; COX-2 specific inhibitors; NSAIDs; Pain Nonst eroidal anti-inflammatory drugs (NSAIDs) are among the most widely used medications in the world because of their demonstrated efficacy in reducing pain and inflammation. 1 Their efficacy has been documented in a number of clinical disorders, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gout, dysmenorrhea, dental pain and headache. [2][3][4][5][6][7][8] The basic mode of action is inhibition of the pro-inflammatory enzyme cyclooxygenase (COX). NSAIDs as a class comprise both traditional nonselective NSAIDs (tNSAIDs) that nonspecifically inhibit both COX-1 and COX-2, and selective COX-2 inhibitors. Although effective at relieving pain and inflammation, tNSAIDs are associated with a significant risk of serious gastrointestinal adverse events with chronic use. 9 Therefore, specific inhibitors of the COX-2 isoenzyme were developed, thus opening the possibility to provide antiinflammatory and analgesic benefits, while theoretically leaving the gastroprotective activity of the COX-1 isoenzyme intact. However, important concerns have recently been raised regarding the potential cardiovascular toxicity of COX-2 inhibitors. 10This review will provide an educational update of the scientific evidence for the efficacy and adverse effects of NSAIDs in view of the emerging new information for this class of drugs. It is composed deliberately to be a classic, pragmatic review and draws on the results of published systematic reviews and studies regarding the topic. It aims to answer the following questions: (1) are there clinically important differences in the efficacy and safety between the different NSAIDs, (2) if there are differences, which are the ones that are more effective and associated with fewer adverse effects, and (3) which are...

show abstract

Section: Effects Of Formulation On the Analgesic Activity Of Nsaidsmentioning

confidence: 99%

An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs

Ong¹,

Lirk²,

Tan³

et al. 2007

Clinical Medicine & Research

482

286

View full text Add to dashboard Cite

show abstract

“…53 The DERP reviews are updated at least annually, and are subject to peer review and public comment before final publication. 54 These sources were sufficient for evaluating most claims, but for six claims, the coders were provided with additional references: publications from head-to-head trials comparing acetaminophen to ibuprofen, [55][56][57][58][59][60][61] IMS Health data from 2008 to evaluate a claim of prescription popularity, 62 nonprescription label information for a discontinued product from an archived web page, 63,64 links to specific nonprescription drug product labels to evaluate the incipient ingredients in the product, 65,66 and a press release providing up-to-date information to support an advertising claim. 67 We only used publicly available evidence to evaluate claims and did not make requests to pharmaceutical companies for unpublished or "on-file" evidence.…”

Section: Coding: Evaluating the Truthfulness Of The Major Claimmentioning

confidence: 99%

Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs

Faerber

Kreling

2013

J GEN INTERN MED

View full text Add to dashboard Cite

BACKGROUND: False and misleading advertising for drugs can harm consumers and the healthcare system, and previous research has demonstrated that physician-targeted drug advertisements may be misleading. However, there is a dearth of research comparing consumer-targeted drug advertising to evidence to evaluate whether misleading or false information is being presented in these ads. OBJECTIVE: To compare claims in consumer-targeted television drug advertising to evidence, in order to evaluate the frequency of false or misleading television drug advertising targeted to consumers. DESIGN: A content analysis of a cross-section of television advertisements for prescription and nonprescription drugs aired from 2008 through 2010. We analyzed commercial segments containing prescription and nonprescription drug advertisements randomly selected from the Vanderbilt Television News Archive, a census of national news broadcasts. MAIN MEASURES: For each advertisement, the mostemphasized claim in each ad was identified based on claim iteration, mode of communication, duration and placement. This claim was then compared to evidence by trained coders, and categorized as being objectively true, potentially misleading, or false. Potentially misleading claims omitted important information, exaggerated information, made lifestyle associations, or expressed opinions. False claims were factually false or unsubstantiated. KEY RESULTS: Of the most emphasized claims in prescription (n=84) and nonprescription (n=84) drug advertisements, 33 % were objectively true, 57 % were potentially misleading and 10 % were false. In prescription drug ads, there were more objectively true claims (43 %) and fewer false claims (2 %) than in nonprescription drug ads (23 % objectively true, 7 % false). There were similar numbers of potentially misleading claims in prescription (55 %) and nonprescription (61 %) drug ads. CONCLUSIONS:Potentially misleading claims are prevalent throughout consumer-targeted prescription and nonprescription drug advertising on television. These results are in conflict with proponents who argue the social value of drug advertising is found in informing consumers about drugs. O ver the past 15 years, drug advertising to consumers has expanded to encompass more products and more channels. Advertising for prescription drugs has become more prevalent, with more products being promoted directly to consumers through traditional ad media such as magazines and television, plus the internet has become an additional means to connect with consumers for both prescription and nonprescription drugs. Drug companies increased their marketing budgets for advertising directly to consumers, particularly for prescription drugs. Prescription drug advertising to consumers totaled $4.8 billion USD in 2009, 1-3 well surpassing consumer promotion for nonprescription products at $3.0 billion USD that year. 4 Also over this time period, patients have become viewed more as consumers of health care, emphasizing shared decisionmaking 5-7 and self-care. [8][9]...

show abstract

“…По силе аналге-зирующего эффекта сопоставим с морфином, значительно превосходит другие НПВП. В экспериментальных исследо-ваниях показано, что неселективные НПВП, подавляющие активность как ЦОГ 2, так и ЦОГ 1, обладают более выра-женным анальгетическим и антигипералгезивным эффек-том по сравнению с селективными ингибиторами ЦОГ 2 [18,19]. Это объясняется существенным повышением активно-сти ЦОГ 1 в ответ на повреждение периферических тканей.…”

unclassified

Cervicogenic headache: pathogenesis, clinical features, diagnosis, therapeutic approaches

Путилина

2011

Neurology, Neuropsychiatry, Psychosomatics

View full text Add to dashboard Cite

Solubilized Ibuprofen: Evaluation of Onset, Relief, and Safety of a Novel Formulation in the Treatment of Episodic Tension‐type Headache

Abstract: Although several other studies have demonstrated the overall analgesic superiority of ibuprofen to acetaminophen, this study demonstrated that the liquigel formulation also provides a clinically relevant advantage for time to analgesic effects.

Cited by 75 publications

References 20 publications

An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs

An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs

Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs

Cervicogenic headache: pathogenesis, clinical features, diagnosis, therapeutic approaches

Contact Info

Product

Resources

About